The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection
Corresponding Author(s) : J.H. Davis
jillian.davis@hamptonu.edu
Cellular and Molecular Biology,
Vol. 53 No. 3: RCMI symposium: Biomedical and clinical research
Abstract
These studies were designed to develop procedures that would capitalize on the growth inhibitory effects of tamoxifen (Tam) and methotrexate (MTX) in breast cancer, while protecting bone marrow with a priming dose of 5-fluorouracil (5-FU). High-dose MTX (10 μM) cytotoxicity is maintained in MCF-7 breast cancer cells but reduced in human bone marrow by a priming and nontoxic dose of 5-FU (10 μM). MTX cytotoxicity is decreased in MCF-7 breast cancer cells when the selective estrogen receptor modulator (SERM) Tam (10 μM) is administered 24 hours prior to 5-FU (10 μM) followed two hours later by MTX (early Tam) resulting in a growth rate of 57.42 ± 4.38% of the control rate. However, when breast cancer cells are exposed to Tam 24 hours after 5-FU + MTX (late Tam), the interaction between MTX and Tam is not antagonistic, the percentage of the control is 29.47 ± 4.54%. Bone marrow exposure to these drug combinations exhibits a protective effect to the MTX cytotoxicity, with the early Tam combination yielding 59.45 ± 16.38% of the control for MTX alone. These studies suggest that a) Tam in combination with a priming dose of 5-FU protects bone marrow from MTX cytotoxicity, b) the interactions between Tam and MTX are sequence-dependent, c) Tam decreases the effect of MTX when Tam administration precedes MTX.
Keywords
Tamoxifen
priming dose of 5-fluorouracil
methotrexate.
Davis, J., Desoto, J., Fryar, E., Southerland, W., & Bowen, D. (2007). Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection. Cellular and Molecular Biology, 53(3), 18–26. Retrieved from https://mail.cellmolbiol.org/index.php/CMB/article/view/1122
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX